Notably, the immunomodulatory drug lenalidomide, commonly used in the treatment of MM, has been reported to reduce MPO levels in mouse models of colitis, and potently reduce MDSC induction in the context of MM.60, 61. This evidence concerns the gene MPO and Miyoshi myopathy.